Martingale Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-21,865
| Closed | -$468K | – | 799 |
|
|
2023
Q2 | $468K | Buy |
21,865
+501
| +2% | +$10.7K | 0.01% | 628 |
|
|
2023
Q1 | $864K | Buy |
21,364
+501
| +2% | +$20.3K | 0.02% | 481 |
|
|
2022
Q4 | $971K | Buy |
20,863
+3,706
| +22% | +$172K | 0.02% | 463 |
|
|
2022
Q3 | $891K | Buy |
17,157
+1,451
| +9% | +$75.4K | 0.02% | 475 |
|
|
2022
Q2 | $743K | Buy |
15,706
+300
| +2% | +$14.2K | 0.01% | 546 |
|
|
2022
Q1 | $1.1M | Buy |
15,406
+100
| +0.7% | +$7.13K | 0.02% | 459 |
|
|
2021
Q4 | $1.15M | Sell |
15,306
-15,152
| -50% | -$1.13M | 0.01% | 457 |
|
|
2021
Q3 | $1.73M | Buy |
30,458
+11,050
| +57% | +$628K | 0.02% | 351 |
|
|
2021
Q2 | $855K | Hold |
19,408
| – | – | 0.01% | 442 |
|
|
2021
Q1 | $958K | Buy |
19,408
+1,399
| +8% | +$69.1K | 0.01% | 437 |
|
|
2020
Q4 | $759K | Sell |
18,009
-22,899
| -56% | -$965K | 0.01% | 517 |
|
|
2020
Q3 | $1.87M | Buy |
40,908
+31,206
| +322% | +$1.43M | 0.02% | 440 |
|
|
2020
Q2 | $488K | Buy |
+9,702
| New | +$488K | 0.01% | 881 |
|